B-1239, a Novel Anti-BAFF-R Afucosylated Human Antibody, Promotes Potent Natural Killer Cell- Mediated Antibody Dependent Cellular Cytotoxicity In Chronic Lymphocytic Leukemia Cells In- Vitro and Depletion Of Circulating Leukemic CLL B Cells In-Vivo.
McWilliams EM, Cheney C, Jones JA, et al.
Key Points:
Authors investigated fully human anti-BAFF-R monoclonal IgG1 antibody in CLL in-vitro and in-vivo.
B-1239 failed to induce complement mediated cytotoxicity.
Binding of B-1239 to CLL cells resulted in enhanced antibody dependent cellular cytotoxicity (ADCC).
One dose injection of B-1239 into Eu-Tcl-1 mice resulted in dramatic reduction in circulating CD5+CD19+ leukemic B cells.
Implications:
- Targeting BAFF-R on CLL cells provides B-cell specific approach for depletion of leukemic CLL cells and provides evidence for therapeutic advantage in BAFF-R therapies in CLL.
View the original abstract on the ASH website.
